MERCK
20.3.2024 16:04:33 CET | Business Wire | Press release
Merck invests more than € 300 million into a new Bioprocessing Production Center in Daejeon, South Korea. The new site is the largest investment by Merck's Life Science business sector in Asia-Pacific to date and demonstrates the company’s commitment to expanding its capacities in the fast-growing region. Merck expects the investment to create approximately 300 additional jobs by the end of 2028.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320613405/en/
Rendering of Merck's new Bioprocessing Production Center in Daejeon, South Korea
“The Asia-Pacific region is home to a large number of institutions that conduct leading-edge and innovative research, manufacturing and services in areas such as biotechnology, mRNA and gene therapy,” said Matthias Heinzel, Member of the Executive Board of Merck and CEO Life Science. “Expanding our presence in the region will bring us even closer to our customers in this evolving and dynamic market. Our goal is to foster deep collaboration to increase the speed in bringing new therapies to patients.”
The facility will support biotechnology and pharmaceutical companies in process development, clinical research and commercial manufacturing of biologics. Biologics are derived from large and complex biological compounds and include products like vaccines, cell and gene therapies, or protein-based therapies, such as monoclonal antibodies. They are one of the fastest-growing class of drugs.
Merck’s new Bioprocessing Production Center will provide essential biotech products such as dry powder cell culture media, process liquids, pre-GMP small-scale manufacturing and sterile sampling systems. Covering an area of 43,000 square meters, the facility will include advanced production capacities, a distribution center and an automated warehouse.
Established in 1989, Merck Korea has been consistently driving dynamic growth of the science and technology industries with more than 1,700 employees across Life Science, Healthcare and Electronics. Merck Korea encompasses 13 sites in production and R&D including the M Lab™ Collaboration Center in Songdo, Incheon which serves biopharmaceutical companies in the region.
Merck’s new site in South Korea is part of a multi-year investment program. It aims to increase the capacity and capabilities of Merck’s Life Science business sector to support the growing global demand for critical drugs and to make significant contributions to public health. Since 2020, Merck has announced industrial capacity and capabilities expansion projects in Life Science throughout Europe, China, and the United States, of more than € 2 billion.
All Merck press releases are distributed by e-mail at the same time they become available on the Merck website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across life science, healthcare and electronics. Around 63,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2023, Merck generated sales of € 21 billion in 65 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as MilliporeSigma in life science, EMD Serono in healthcare, and EMD Electronics in electronics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240320613405/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Launches Process Context for Enterprise AI, Reinforcing Position as the Essential Platform for AI Ecosystem20.10.2026 14:00:00 CEST | Press release
Process Context for Enterprise AI provides vital business understanding for the AI ecosystem – helping enterprises unlock greater AI value, fasterNew capabilities improve operational performance, identify where AI can deliver the most value and give agents access to trusted process contextCombines Object-Centric Process Mining (OCPM), Process Lens and Model Context Protocol (MCP) to create essential platform for agentic AI at scale ARIS, the pioneer in business process management whose powerful Enterprise Model has been the foundation for enterprise operations for more than three decades, today launched Process Context for Enterprise AI – to become the critical base layer for the agentic ecosystem, giving agents and applications the business understanding they need to deliver measurable new value. While Process Context is becoming critical for successfully deploying and scaling enterprise AI, it demands far more than simply connecting AI agents to business data. It requires a comprehen
Visa, BILL and Billtrust Launch First Live Pilot for Trusted AI Agent Payments Between Buyer and Supplier Platforms20.10.2026 14:00:00 CEST | Press release
Demonstrates how trusted AI agents are moving beyond automation to act on behalf of buyers and suppliers in real-world commercial transactions. Visa (NYSE: V), BILL (NYSE: BILL) and Billtrust today announced they have launched the first live pilot to enable trusted AI agents to initiate and complete approved buyer invoice payments end-to-end through supplier portals. Until now, many payment portals relied on human authentication requirements that limited how approved payments could be automated. Together, with leading accounts payable and receivable solutions providers BILL and Billtrust, the Visa Intelligent CommerceTM portfolio helps bridge that gap. Leveraging offerings such as Visa Trusted Agent Protocol, AI agents can now be securely authenticated to credentialed portals. As a result, buyer payments that previously relied on manual entry can be completed by trusted AI agents, while preserving supplier control and oversight. How trusted AI agents are overcoming one of payment autom
Parse Biosciences Launches Evercode MAX, Enabling Researchers to Profile More Cells and Samples with Greater Flexibility20.10.2026 14:00:00 CEST | Press release
New modular platform gives researchers greater control over sample and cell throughput while optimizing value Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode™ MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using the same instrument-free workflow, researchers can profile up to 2.5 times as many cells across up to twice as many samples within their existing budget, or run the same experiment at roughly half the overall cost. Evercode MAX enables researchers to build a kit configuration around their experiment, with sample barcoding and library preparation as independent kits. Evercode MAX is available for Whole Transcriptome, WT FFPE, TCR, BCR, and CRISPR Detect. With configurations supporting up to 384 samples and 2 million cells, researchers can prioritize more samples to characterize biological variation or more cells per s
Hologic and Inpeco Announce Co-Marketing Partnership to Advance Molecular Laboratory Automation20.10.2026 14:00:00 CEST | Press release
Hologic, Inc., a global leader in women’s health and diagnostics, and Inpeco S.A., the global leader in Total Laboratory Automation, today announced they have signed a co-marketing partnership for Inpeco’s automation solution FlexLab™ X and Hologic’s Panther® System in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020837126/en/ Hologic and Inpeco S.A. announce a co-marketing partnership for Inpeco's automation solution FlexLab™ X and Hologic’s Panther® System in Europe. Inpeco’s recently launched FlexLab X system enables laboratories to connect multiple Panther Systems. By combining Hologic’s fully-automated molecular diagnostics platform with FlexLab X‘s open automation capabilities, laboratories can achieve high-throughput workflows with the potential to increase sample volumes1 and enhance end-to-end sample traceability2, supporting reliable test results for optimal patient outcomes.3 The Panther System will i
FiRa Consortium Launches Core 4.1 Specifications and Enhanced Certification Program20.10.2026 14:00:00 CEST | Press release
FiRa Core 4.1 expands secure, private, and interoperable FiRa deployments. The FiRa® Consortium today announced the release of the FiRa Core 4.1 Specifications and an updated 4.1 Certification Program to help advance ultra-wideband (UWB) interoperability within the FiRa ecosystem. Core 4.1 introduces enhancements for FiRa Untracked Navigation, expanded cryptographic security certification, and additional support for concurrent ranging and data capabilities across multi-vendor FiRa deployments. The release supports deployment requirements defined by the FiRa Frameworks and Profiles Sub-Group (FPSG), including high-density indoor positioning, hardware-level security, and concurrent data capabilities for FiRa use cases. Features of the FiRa Core 4.1 Specifications and Certification ProgramEnhanced Downlink Time Difference of Arrival (DL-TDoA) for FiRa Untracked Navigation — Adds coordinate-system and anchor-location encoding options, including floor identification without increasing messa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom